ARS Pharmaceuticals Stock (NASDAQ:SPRY)
Previous Close
$11.75
52W Range
$2.55 - $16.50
50D Avg
$11.17
200D Avg
$8.48
Market Cap
$1.10B
Avg Vol (3M)
$1.03M
Beta
0.77
Div Yield
-
SPRY Company Profile
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Performance
Peer Comparison
Ticker | Company |
---|---|
CUE | Cue Biopharma, Inc. |
CFRX | ContraFect Corporation |
CNSP | CNS Pharmaceuticals, Inc. |
TCRX | TScan Therapeutics, Inc. |
AVRO | AVROBIO, Inc. |
DRMA | Dermata Therapeutics, Inc. |
ANNX | Annexon, Inc. |
WVE | Wave Life Sciences Ltd. |
ALLR | Allarity Therapeutics, Inc. |
IMMX | Immix Biopharma, Inc. |
INAB | IN8bio, Inc. |
TFFP | TFF Pharmaceuticals, Inc. |
WINT | Windtree Therapeutics, Inc. |
CGTX | Cognition Therapeutics, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
ZURA | Zura Bio Limited |
PALI | Palisade Bio, Inc. |